Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Likes Its Go-It-Alone Strategy Over A Mega-Merger

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline’s solo strategy is the right one, CEO Andrew Witty said, brushing aside questions about a potential merger with Pfizer during the company’s third quarter sales and earnings call.

You may also be interested in...



Swapping Assets Now Down To Execution For GSK And Novartis

Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.

GSK’s Darapladib Poised To Become Latest Cardiovascular Outcomes Casualty

Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.

Pfizer and BioNTech To Initiate COVID-19 Vaccine Clinical Trials In April

The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel